OCUL logo

OCUL
Ocular Therapeutix Inc

12,040
Mkt Cap
$2.12B
Volume
521,937.00
52W High
$16.44
52W Low
$6.23
PE Ratio
-6.65
OCUL Fundamentals
Price
$9.60
Prev Close
$9.68
Open
$9.62
50D MA
$9.11
Beta
1.46
Avg. Volume
3.22M
EPS (Annual)
-$1.42
P/B
3.64
Rev/Employee
$159,849.23
$1,613.02
Loading...
Loading...
News
all
press releases
Ocular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of Canada
Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Ocular Therapeutix Q1 Earnings Call Highlights
Ocular Therapeutix (NASDAQ:OCUL) management used its first-quarter 2026 earnings call to highlight clinical and regulatory progress for AXPAXLI, the company's investigational therapy for wet...
MarketBeat·3d ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $10.79 million for the quarter...
MarketBeat·3d ago
News Placeholder
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving Average - Here's What Happened
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Ocular Therapeutix (NASDAQ:OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works...
MarketBeat·11d ago
News Placeholder
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC
Deltec Asset Management LLC cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F...
MarketBeat·11d ago
News Placeholder
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts
Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, MarketBeat.com...
MarketBeat·19d ago
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Trading 10.2% Higher - Here's What Happened
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 10.2% - Still a Buy...
MarketBeat·21d ago
News Placeholder
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.read more...
Benzinga·25d ago
<
1
2
...
>

Latest OCUL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.